

REPL::ANNUAL GENERAL MEETING::VOLUNTARY

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Security

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Announcement Details

Announcement Title

Annual General Meeting

Date & Time of Broadcast

28-Apr-2021 18:48:13

Status

Replacement

Announcement Reference

SG210412MEET140H

Submitted By (Co./ Ind. Name)

Lim Sher Mei (Lin Shimei)

Designation

Company Secretary

Financial Year End

31/12/2020

Event Narrative

Narrative Type	Narrative Text
Additional Text	Please refer to the attached with regards to the Annual General Meeting ("AGM") held on 28 April 2021: 1) Presentation slides 2) Results of the AGM 3) Minutes of the AGM
Additional Text	This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("Sponsor") for compliance with the Singapore Exchange Securities Trading Limited ("SGXST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.
Additional Text	This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.
Additional	The contact person for the Sponsor is Mr Kelvin Wong, Senior Vice President. The contact

Text	particulars are 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.
------	---

Event Dates

Meeting Date and Time

28/04/2021 14:00:00

Response Deadline Date

25/04/2021 14:00:00

Event Venue(s)

Place

Venue(s)	Venue details
Meeting Venue	The Annual General Meeting ("AGM") of the Company will be convened and held by way of electronic means. Shareholders will not be able to attend the AGM in person.

Attachments

[Hyphens AGM FY2020 Presentation slides 28042021.pdf](#)

[Hyphens Annt Results of AGM 28042021.pdf](#)

[Hyphens AGM Minutes 28042021.pdf](#)

Total size =6335K MB

Related Announcements

Related Announcements

[13/04/2021 00:38:44](#)

[12/04/2021 18:27:55](#)



HYPHENS PHARMA INTERNATIONAL LIMITED

3RD ANNUAL GENERAL MEETING

28 APRIL 2021



DISCLAIMER

This presentation has been prepared by Hyphens Pharma International Limited (the "**Company**" and, together with its subsidiaries, the "**Group**").

This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated, photographed or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated or quoted, directly or indirectly, to any person either in your organisation or elsewhere. None of the Company, DBS Bank Ltd. (the "**Sponsor**") nor any of their respective affiliates, advisors and representatives makes any representation regarding, or assumes any responsibility or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of the content in this presentation.

By attending or viewing all or part of this presentation, you:

- i. represent and warrant that you are lawfully able to receive this presentation under the laws of the jurisdiction in which you are located and all other applicable laws;
- ii. agree to be bound by the limitations and restrictions described herein; and
- iii. agree to maintain confidentiality regarding the information disclosed in this presentation and to continue to adhere to all applicable securities and insider trading rules and laws in any jurisdiction at all times.

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information in this presentation is a summary only and does not purport to contain all of the information that may be required to evaluate the Company or any potential transaction. Any potential transaction could be made available to you in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to you, herein or otherwise. Information in this presentation is qualified in its entirety by reference to an offering document for any potential transaction, if it proceeds.

None of the Company, the Sponsor, and any of their respective holding companies, subsidiaries, associated undertakings, controlling persons, affiliates, and any of their respective directors, officers, partners, employees, agents, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. It is not the intention to provide, and you may not rely on the content of this presentation as providing, a complete or comprehensive analysis of the Company's or the Group's financial or trading position or prospects. The information and opinions contained in this presentation is provided as at the date hereof (unless otherwise indicated) and are subject to change without notice. This presentation may not contain all material information concerning the Company or the Group.

The information contained in this presentation has not been independently verified. The accuracy and completeness of the information and opinions in this presentation is not guaranteed and no representation or warranty, expressed or implied, is made as to, and no reliance, in whole or in part, should be placed on the fairness, accuracy, completeness or correctness of the information, opinions or assumptions contained herein. Further, nothing in this presentation should be construed as constituting legal, business, tax or financial advice. None of the Sponsor and its subsidiaries or affiliates has independently verified, approved or endorsed the material herein.

The information in this presentation includes historical information about and relevant to the Group that should not be regarded as an indication of the future performance of the Group or the value of the shares of the Company. This presentation also contains forward-looking statements that may be identified by their use of words like "plans", "expects", "will", "anticipates", "believes", "intends", "depends", "projects", "estimates" or other words of similar meaning and that involve assumptions, risks and uncertainties. All statements that address expectations or projections about the future and all statements other than statements of historical facts included in this presentation, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Such forward-looking statements are based on certain assumptions and expectations of future events regarding the Group's present and future business strategies and the environment in which the Group will operate, and must be read together with those assumptions. No assurance or guarantee is given that these assumptions and expectations are accurate or will be realised. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. These risks, uncertainties and assumptions include, without limitation, general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other entities, shifts in customer demand, customers and partners, changes in operating expenses including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Group. Past performance is not necessarily indicative of future performance. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the Company's current view of future events. None of the Company and the Sponsor, their respective affiliates and their respective agents assumes any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

Neither this presentation nor any of its content may be used without the prior written consent of the Company and the Sponsor. Any forwarding, distribution or reproduction of the information in this presentation electronically or otherwise, in whole or in part, is unauthorised.




CORPORATE PRESENTATION



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



OUR STRATEGIC FOCUS



ASEAN's Leading
Pharmaceuticals &
Consumer Healthcare
Group



Long-Term Goal
Asia's No. 1
Skin Health
Company



OUR BUSINESS SEGMENTS

1

Specialty Pharma Principals

2

Proprietary Brands

Ceradan

TDF

CG 210

Ocean Health

3

Medical Hypermart and Digital



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



ANNUAL REPORT 2020



- + Deepening Digital Capabilities
- + Expanding Regionally
- + Widening Product Portfolio
- + Creating Value via Intangible Assets
- + Supporting Community Outreach
- + Financial Performance
- + Rewarding Shareholders



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group





DEEPENING DIGITALISATION CAPABILITIES



Building the

Digital Transformation

Talent Pool

- + Senior Manager, Digital Transformation
- + E-Commerce & Digital Services Manager
- + Associate E-Commerce Manager





EXPANDING REGIONALLY



Shanghai
Good Luck
上海古腊国际
贸易有限公司

Mainland China

JSPharma

South Korea



Healthguard
Pharmacy
Limited

Sri Lanka



SUTL HK

Hong Kong, Macau
and Duty-Free
Channels in China



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



3

WIDENING PRODUCT PORTFOLIO



- + Hyphens has acquired the **rights, titles** and interests in the **trademarks** of CG 210® for Singapore & Malaysia
- + CG 210® is a globally renowned & patented topical botanical hair growth-promoting agent
- + New brand ownership adds to our **Proprietary Brands** business segment
- + Inclusion of scalp care as part of our **dermatology** portfolio





WIDENING PRODUCT PORTFOLIO

- + Patent for Ceradan® Advanced technology in UK.
- + Patent pending in 13 other countries/ region.
- + New product launches:
- + Ceradan® facelift:





Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group






WIDENING PRODUCT PORTFOLIO





4 CREATING VALUE VIA INTANGIBLE ASSETS





SUPPORTING COMMUNITY OUTREACH



**HAND IN HAND
TOGETHER WITH YOU**



to give back to our communities




Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group




6.1 FINANCIAL PERFORMANCE


Revenue (S\$'m)



Profit After Tax (S\$'m)




6.2 REVENUE BY BUSINESS SEGMENTS





6.3 EBITDA BY BUSINESS SEGMENTS



EBITDA margin

Specialty	10.4%	9.5%	9.4%
Proprietary	6.8%	6.9%	12.1%
Hypermart	5.0%	8.5%	2.7%





REWARDING SHAREHOLDERS

S\$'000	Dividend	Yield ^(a)	Div / NP ^(b)
FY2020 (subj to shareholders' approval)	0.62 cents	1.9%	30.2%
FY2019	1 cent	3.1%	46.0%
FY2018	0.55 cents	1.7%	30.5%

- (a) Yield is computed based on total dividends declared for the financial year divided by closing price of S\$0.32 @ 23 April 2021.*
- (b) Dividend policy: to pay at least 30% of its net profits attributable to shareholders, subject to the Board's approval.*



BUSINESS OUTLOOK



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



INVESTING FOR GROWTH

1. Investment in Proprietary Brands
2. Internationalisation
3. Going Digital
4. Strengthen Specialty Pharma portfolio
5. Acquisitions
6. Challenges – COVID-19



QUESTIONS & ANSWERS



QUESTIONS FROM SHAREHOLDERS

- Q1:** For the past 3 years, Group revenue is stagnant at around S\$120 million and profit net of tax is also stagnant at around S\$6 million. Is the Company concerned with this stagnation? Where is the growth going to come from, both top line and bottom line?
- Q2:** Hyphens markets & sells a range of specialty pharmaceutical products in selected ASEAN countries, and has strong regulatory capabilities as well as significant experience in certain therapeutic areas/ medical specialties. As such, (a) Is Hyphens actively seeking to leverage this strong capability to expand the distribution of the specialty pharmaceutical products to the rest of the ASEAN countries where Hyphens has no direct presence? (b) Are there plans to synchronise the distribution of its full range of specialty pharmaceutical products across the ASEAN countries?



QUESTIONS FROM SHAREHOLDERS

- Q3:** Although the China market holds enormous opportunities, it is also very competitive. As such, can the management please share the China expansion/ marketing strategy for Ceradan? Where/How is Ceradan sold in China?
- Q4:** Why did Hyphens only market TDF Fairence in the South Korea market? Is there potential to expand the rest of the TDF range in South Korea?
- Q5:** CG210 is available in retail channels only in Malaysia. Are there plans to bring the CG 210 range into the retail channels in Singapore?



QUESTIONS FROM SHAREHOLDERS

- Q6:** Why did revenue of Medical Hypermart & Digital segment increase from S\$39.8 million to S\$40.8 million yet EBITDA declined from S\$3.4 million to S\$1.1 million? Did you face more competition that necessitated a reduction in your margins?
- Q7:** Hyphens had signed a memorandum of understanding with Doctor Anywhere, and was awarded e-pharmacy license for WellAway Pharmacy. Other than telemedicine and perhaps onboarding more products / end customers in the B2B platform, are there any other major potential avenues for business growth in the Medical Hypermart segment?



RESOLUTIONS



RESOLUTION 1

To receive and adopt the Directors' Statement and Audited Financial Statements of the Company for the financial year ended 31 December 2020 together with the Auditors' Report thereon.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
241,290,256	100	-	-	-



RESOLUTION 2

To declare a **final tax exempt (one-tier) dividend of 0.62 Singapore cents per ordinary share** for the financial year ended 31 December 2020.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
241,290,256	100	-	-	-



RESOLUTION 3

To re-elect **Mr Heng Wee Koon** under Regulation 97 of the Constitution.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
234,669,056	97.26	6,621,200	2.74	-



RESOLUTION 4

To re-elect **Mr Ng Eng Leng** under Regulation 97 of the Constitution.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
234,669,056	97.26	6,621,200	2.74	-



RESOLUTION 5

To re-elect **Mr Chan Kiat** under Regulation 103 of the Constitution.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
241,290,256	100	-	-	-



RESOLUTION 6

To approve the Directors' fees of **SGD 184,900** for the year ended 31 December 2020.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
126,863,895	100	-	-	114,426,361



RESOLUTION 7

To re-appoint **RSM Chio Lim LLP** as auditors of the Company and to authorise the Directors to fix their remuneration.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
234,669,056	97.26	6,621,200	2.74	-



RESOLUTION 8

To authorise Directors to allot and issue **new shares** pursuant to Section 161 of the Companies Act (Chapter 50) and Rule 806 of the SGX-ST Listing Manual Section B: Rule of Catalyst.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
234,622,900	97.24	6,667,356	2.76	-



RESOLUTION 9

To authorise Directors to grant awards and issue shares in accordance with **Hyphens Performance Share Plan**.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
120,127,339	94.75	6,657,356	5.25	114,505,561



RESOLUTION 10

To authorise Directors to grant options and issue shares in accordance with **Hyphens Share Option Scheme**.

Votes in Favour		Votes Against		Abstained
No. of shares	%	No. of shares	%	No. of shares
120,127,339	94.75	6,657,356	5.25	114,505,561



SCRUTINEER'S CERTIFICATE

 **DREW CORP SERVICES**
A WHOLLY-OWNED SUBSIDIARY OF DREW & NAPIER LLC

General Line
T : +65 6531 2266
F : +65 6533 1542

DrewCorp Services Pte Ltd
10 Collyer Quay
#10-01 Ocean Financial Centre
Singapore 049315

www.drewnapier.com/drewcorp

26 April 2021

To: The Board of Directors
Hyphens Pharma International Limited (*Issuer*)

Dear Sirs,

As scrutineer appointed for the poll conducted at the Annual General Meeting of the Issuer held by way of electronic means on 28 April 2021, we hereby certify that the results of the poll (rounded to the nearest 2 decimal places) are correctly set out below:

No.	For	For %	Against	Against %	Total No. of Voting Shares	Total %
Resolution 1	241,290,256	100.00	0	0.00	241,290,256	100.00
Resolution 2	241,290,256	100.00	0	0.00	241,290,256	100.00
Resolution 3	234,669,056	97.26	6,621,200	2.74	241,290,256	100.00
Resolution 4	234,669,056	97.26	6,621,200	2.74	241,290,256	100.00
Resolution 5	241,290,256	100.00	0	0.00	241,290,256	100.00
Resolution 6	126,863,895	100.00	0	0.00	126,863,895	100.00
Resolution 7	234,669,056	97.26	6,621,200	2.74	241,290,256	100.00
Resolution 8	234,622,900	97.24	6,667,356	2.76	241,290,256	100.00
Resolution 9	120,127,339	94.75	6,657,356	5.25	126,784,695	100.00
Resolution 10	120,127,339	94.75	6,657,356	5.25	126,784,695	100.00

Yours faithfully,



DrewCorp Services Pte Ltd



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group





Hyphens Pharma International Limited (SGX: 1J5)
16 Tai Seng Street, Level 4, Singapore 534138
www.hyphensgroup.com

in | Follow us on LinkedIn

1. **RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 APRIL 2021**
 2. **RE-APPOINTMENT OF DIRECTORS**

1. **RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 APRIL 2021**

The Board of Directors of Hyphens Pharma International Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 13 April 2021 were duly passed by the shareholders of the Company by way of poll at the Annual General Meeting (“**AGM**”) held on 28 April 2021.

The information as required under Rule 704(15) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rule of Catalyst (“**Catalist Rules**”) is set out below:

(a) Poll Results

The results of the poll on each of the resolutions passed at the AGM are as follows:

Resolution Number and Details	Total No. of Shares Represented by Votes For and Against	For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
Ordinary Resolution 1 To receive and adopt the Directors’ Statement and Audited Financial Statements of the Company for the financial year ended 31 December 2020 together with the Auditors’ Report thereon.	241,290,256	241,290,256	100.00	-	-

Resolution Number and Details	Total No. of Shares Represented by Votes For and Against	For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
Ordinary Resolution 2 To declare a final tax exempt (one-tier) dividend of 0.62 Singapore cents per ordinary share for the financial year ended 31 December 2020	241,290,256	241,290,256	100.00	-	-
Ordinary Resolution 3 To re-elect Mr Heng Wee Koon as Director	241,290,256	234,669,056	97.26	6,621,200	2.74
Ordinary Resolution 4 To re-elect Mr Ng Eng Leng as Director	241,290,256	234,669,056	97.26	6,621,200	2.74
Ordinary Resolution 5 To re-elect Mr Chan Kiat as Director	241,290,256	241,290,256	100.00	-	-
Ordinary Resolution 6 To approve the Directors' fees of SGD 184,900 for the financial year ended 31 December 2020	126,863,895	126,863,895	100.00	-	-

Resolution Number and Details	Total No. of Shares Represented by Votes For and Against	For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
Ordinary Resolution 7 To re-appoint RSM Chio Lim LLP as auditors of the Company and authorise the Directors to fix their remuneration	241,290,256	234,669,056	97.26	6,621,200	2.74
Ordinary Resolution 8 Authority to allot and issue shares	241,290,256	234,622,900	97.24	6,667,356	2.76
Ordinary Resolution 9 Authority to grant awards and issue shares in accordance with Hyphens Share Plan	126,784,695	120,127,339	94.75	6,657,356	5.25
Ordinary Resolution 10 Authority to grant options and issue shares in accordance with Hyphens Share Option Scheme.	126,784,695	120,127,339	94.75	6,657,356	5.25

(b) Abstention from Voting

Details of parties who have abstained from voting on the resolutions tabled at the AGM are set out below:

Resolution Number and Details	Name	Number of Shares Held
Ordinary Resolution 6 To approve the Directors' fees of SGD 184,900 for the financial year ended 31 December 2020	Tan Chwee Choon ⁽ⁱ⁾ Tan Kia King ⁽ⁱⁱ⁾	114,426,361
Ordinary Resolution 9 ⁽ⁱⁱⁱ⁾ Authority to grant awards and issue shares in accordance with Hyphens Share Plan	Employees and others who are eligible to participate in the Hyphens Share Plan	114,505,561
Ordinary Resolution 10 ⁽ⁱⁱⁱ⁾ Authority to grant options and issue shares in accordance with Hyphens Share Option Scheme.	Employees and others who are eligible to participate in the Hyphens Share Option Scheme	114,505,561

Note:

- (i) Mr Tan Chwee Choon had abstained from voting on the resolution although he was not a recipient to the Directors' fee.
- (ii) Dr Tan Kia King had abstained from voting on the resolution as it was relating to his own fee.
- (iii) No party was required to abstain from voting on the resolutions put to the AGM. Nonetheless, as good corporate governance, all Directors and employees of the Group, who are also shareholders and are eligible to participate in the Hyphens Share Plan and the Hyphens Share Option Scheme, including proxies of such shareholders, are requested to abstain from voting at the AGM in respect of Ordinary Resolutions 9 and 10.

(c) Scrutineer

Drewcorp Services Pte Ltd was appointed as the Company's scrutineer for the AGM.

2. RE-APPOINTMENT OF DIRECTORS – STATEMENT PURSUANT TO RULE 704(7) OF THE CATALIST RULES

- (a) Mr Heng Wee Koon was re-elected as a Director of the Company, he shall remain as the Lead Independent Director, the Chairman of the Audit Committee, a member of the Nominating Committee and a member of the Remuneration Committee and shall be considered independent for the purpose of Rule 704(7) of the Rules of Catalist.
- (b) Mr Ng Eng Leng was re-elected as a Director of the Company, he shall remain as the Chairman of the Remuneration Committee and a member of the Audit Committee and shall be considered independent for the purpose of Rule 704(7) of the Rules of Catalist.
- (c) Mr Chan Kiat was re-elected as a Director of the Company, he shall remain as a member of the Audit Committee and a member of the Remuneration Committee and shall be considered independent for the purpose of Rule 704(7) of the Rules of Catalist.

BY ORDER OF THE BOARD

Lim See Wah
Executive Chairman and Chief Executive Officer
Date: 28 April 2021

*This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.

3RD ANNUAL GENERAL MEETING

Date : 28 April 2021
Place : Video conferencing
Present : Refer to the Attendance List

CHAIRMAN

Mr Lim See Wah presided at the meeting.

QUORUM

After ascertaining the presence of a quorum, the Chairman called the meeting to order at 2.00 p.m.

INTRODUCTION

Chairman welcomed the shareholders to the 3rd Annual General Meeting ("AGM") of the Company and introduced the members of the Board to the shareholders.

The Company informed the shareholders of the following:-

- a) In accordance with the Company's Constitution, electronic voting was not allowed. Shareholders who wish to vote on any or all of the resolutions would have submitted their proxy form to appoint the Chairman to vote on their behalf.
- b) Shareholders' microphones would be muted to avoid audio interference during the course of the AGM

A presentation was made to the shareholders to update them on the Group's businesses.

QUESTIONS & ANSWERS

The Company has received questions from shareholders. The Board and Management addressed some of these questions. The full written response is attached in Appendix A.

NOTICE

A copy of the Company's Notice of AGM had been circulated to the shareholders on 13 April 2021. The Notice of the AGM, with the consent of the shareholders, was taken as read.

RESOLVED -

RESOLUTION 1 - DIRECTORS' REPORT AND ACCOUNTS

That the audited financial statements and the Reports of the Directors and Auditors for the year ended 31 December 2020 submitted to this Meeting be and are hereby received.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	241,290,256	100.00
No. of votes against the Resolution	-	-
No. of votes abstained from voting on the Resolution	-	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 2 – DECLARATION OF FINAL DIVIDEND

That the Company do hereby approve a final exempt (one-tier) dividend of 0.62 Singapore cents per share for the year ended 31 December 2020 based on the issued and fully paid ordinary shares and that such dividend be paid on 25 May 2021 to the shareholders registered with the Company on 12 May 2021.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	241,290,256	100.00
No. of votes against the Resolution	-	-
No. of votes abstained from voting on the Resolution	-	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 3 - RE-ELECTION OF DIRECTOR

That Mr Heng Wee Koon be and is hereby re-elected as Director of the Company in accordance with Regulation 97 of the Company's Constitution.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	234,669,056	97.26
No. of votes against the Resolution	6,621,200	2.74
No. of votes abstained from voting on the Resolution	-	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 4 – RE-ELECTION OF DIRECTOR

That Mr Ng Eng Leng be and is hereby re-elected as Director of the Company in accordance with Regulation 97 of the Company's Constitution.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	234,669,056	97.26
No. of votes against the Resolution	6,621,200	2.74
No. of votes abstained from voting on the Resolution	-	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 5 – RE-ELECTION OF DIRECTOR

That Mr Chan Kiat be and is hereby re-elected as Director of the Company in accordance with Regulation 103 of the Company's Constitution.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	241,290,256	100.00
No. of votes against the Resolution	-	-
No. of votes abstained from voting on the Resolution	-	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 6 – DIRECTORS’ FEES

That the Directors’ fees of SGD 184,900 for the year ended 31 December 2020 be hereby approved.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	126,863,895	100.00
No. of votes against the Resolution	-	-
No. of votes abstained from voting on the Resolution	114,426,361	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 7 - RE-APPOINTMENT OF AUDITORS

That Messrs RSM Chio Lim LLP be and they are hereby re-appointed as Auditors of the Company, to hold office until the conclusion of the next Annual General Meeting and that the Directors be and are hereby authorised to fix their remuneration.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	234,669,056	97.26
No. of votes against the Resolution	6,621,200	2.74
No. of votes abstained from voting on the Resolution	-	-

The Chairman declared the motion carried.

SPECIAL BUSINESSES

RESOLVED -

RESOLUTION 8 – AUTHORITY TO ALLOT AND ISSUE SHARES

That pursuant to Section 161 of the Companies Act (Chapter 50) of Singapore (“**Companies Act**”) and Rule 806 of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”), authority be and is hereby given to the Directors of the Company to allot and issue shares and/or convertible securities in the capital of the Company (whether by way of rights, bonus or otherwise) at any time and upon such terms and conditions and for such purposes and to such persons as the Directors of the Company may in their absolute discretion deem fit provided that:

- (i) the aggregate number of shares and/or convertible securities to be issued pursuant to this resolution must not be more than one hundred per cent (100%) of the total number of issued shares excluding treasury shares and subsidiary holdings of the Company (as calculated in accordance with sub-paragraph (ii) below), of which the aggregate number of shares and/or convertible securities to be issued other than on a *pro-rata* basis to existing shareholders of the Company must not be more than fifty per cent (50%) of the total number of issued shares excluding treasury shares and subsidiary holdings of the Company (as calculated in accordance with sub-paragraph (ii) below);
- (ii) (subject to such manner of calculations as may be prescribed by the SGX-ST), for the purpose of determining the aggregate number of shares that may be issued under sub-paragraph (i) above, the total number of issued shares excluding treasury shares and subsidiary holdings shall be based on the total number of issued shares excluding treasury shares and subsidiary holdings of the Company at the time this resolution is passed after adjusting for:
 - (a) new shares arising from the conversion or exercise of any convertible securities;
 - (b) new shares arising from exercising share options or vesting of share awards provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and
 - (c) any subsequent bonus issue, consolidation or sub-division of shares;
- (iii) in exercising the authority conferred by this resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST) and the Company's Constitution; and
- (iv) unless revoked or varied by the Company in a general meeting, the authority conferred by this resolution shall continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier.

Proposer : Chairman
 Seconded : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	234,622,900	97.24
No. of votes against the Resolution	6,667,356	2.76
No. of votes abstained from voting on the Resolution	-	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 9 - AUTHORITY TO GRANT AWARDS AND TO ALLOT AND ISSUE SHARES IN ACCORDANCE WITH HYPHENS PERFORMANCE SHARE PLAN

That pursuant to Section 161 of the Companies Act (Chapter 50) and the Rules of Catalist, approval be and is hereby given to the Directors of the Company to:

- (i) offer and grant awards in accordance with the provisions of the Hyphens Performance Share Plan ("the **Performance Share Plan**"); and

- (ii) and issue from time to time such number of fully paid-up shares in the capital of the Company as may be required to be allotted and issued pursuant to the vesting of awards under the Performance Share Plan, provided always that the aggregate number of Shares issued and/or issuable pursuant to the Performance Share Plan, the Share Option Scheme and any other share based incentive schemes of the Company shall not exceed 15% of the total number of issued shares in the capital of the Company (excluding treasury shares and subsidiary holdings, if any) from time to time.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	120,127,339	94.75
No. of votes against the Resolution	6,657,356	5.25
No. of votes abstained from voting on the Resolution	114,505,561	-

The Chairman declared the motion carried.

RESOLVED -

RESOLUTION 10 - AUTHORITY TO GRANT OPTIONS AND TO ALLOT AND ISSUE SHARES IN ACCORDANCE WITH HYPHENS EMPLOYEE SHARE OPTION SCHEME

That pursuant to Section 161 of the Companies Act (Chapter 50) and the Rules of Catalyst, approval be and is hereby given to the Directors of the Company to:

- (i) offer and grant Options in accordance with the provisions of the Hyphens Share Option Scheme ("the **Share Option Scheme**"); and
- (ii) to allot and issue from time to time such number of fully paid-up shares as may be required to be allotted and issued pursuant to the exercise of the Options under the Share Option Scheme, provided always that the aggregate number of Shares issued and/or issuable pursuant to the Share Option Scheme, the Performance Share Plan and any other share based incentive schemes of the Company shall not exceed 15% of the total number of issued shares (excluding treasury shares and subsidiary holdings, if any) from time to time.

Proposer : Chairman
 Seconder : Fang Lee Wei

The motion was put to vote by poll and the results were as follows:-

	No.	Percentage (%)
No. of votes in favour of the Resolution	120,127,339	94.75
No. of votes against the Resolution	6,657,356	5.25
No, of votes abstained from voting on the Resolution	114,505,561	-

The Chairman declared the motion carried.

TERMINATION OF MEETING

There being no other business, the Meeting ended at 2.25 p.m. with a vote of thanks to the Chair.

CONFIRMED AS A TRUE RECORD OF MINUTES

LIM SEE WAH

Chairman

*This document has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this document.*

This document has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.

ATTENDANCE LISTS

Physical attendance

Name	Position
Lim See Wah	Executive Chairman and CEO
Heng Wee Koon	Lead Independent Director
Lim Sher Mei (Lin Shimei)	Company Secretary
Fang Lee Wei	Chief Financial Officer

Attendance via web conference

Board of Directors

Name	Position
Tan Chwee Choon	Executive Director
Tan Kia King	Non-Executive Director
Ng Eng Leng	Independent Director
Tan Seok Hoong @Mrs Audrey Liow	Independent Director
Chan Kiat	Independent Director

Professionals

Company Name	
Boardroom Corporate & Advisory Services Pte Ltd	Share registrar / Poll agent
Drewcorp Services Pte Ltd	Scrutineer
DBS Bank Ltd	Sponsor
RSM Chio Lim LLP	Independent Auditor
Stone Forest Corpserve Pte. Ltd.	Corporate Secretarial

Shareholders

Due to the restriction on the use of personal data pursuant to the provisions of the Personal Data Protection Act 2012, the names of the shareholders present at the meeting will not be published in this minutes.

Appendix A

Question 1

Why did revenue of Medical Hypermart & Digital segment increase from S\$39.8 million to S\$40.8 million yet EBITDA declined from S\$3.4 million to S\$1.1 million? Did you face more competition that necessitated a reduction in your margins?

Company's Response

The lower EBITDA in FY2020 was mainly due to:

- (i) S\$1.3m of impairment allowance on inventories obsolescence; and
- (ii) Absence of a tender sales recorded in FY2019 which had good margin.

If the above two factors were excluded, EBITDA margin of Medical Hypermart & Digital segment in FY2020 would have been comparable with that in FY2019.

Question 2

For the past 3 years, Group revenue is stagnant at around S\$120 million and profit net of tax is also stagnant at around S\$6 million. Is the Company concerned with this stagnation? Where is the growth going to come from, both top line and bottom line?

Company's Response

Revenue of our Specialty Pharma Principals segment, which is the Group's largest business segment, was adversely affected by COVID-19 and showed a decline in FY2020, thereby curtailing the Group's revenue. Management will focus on executing the 5 growth strategies outlined in the CEO's presentation.

Question 3

Did the Company see increased demand for its products due to COVID-19? If so, which product(s)? What percentage of the revenue increase is attributed to COVID-19? Is this increase in revenue sustainable, going forward?

Company's Response

Although the Group saw an increase in demand for personal protection equipment ("PPE") and health supplements, these contributed to less than 5% of the Group's revenue in FY2020. Given the relatively small contribution, we expect continual growth in revenue barring any unforeseen circumstances.

Question 4

Is Hyphens able to tap onto any of our local government's schemes (e.g. Enterprise Singapore, IMDA) to help local enterprises grow its capabilities, e.g. overseas expansion, going digital, etc?

Company's Response

Yes, we are constantly tapping support from various government agencies to develop our capabilities in relevant aspects.

Question 5

Hyphens had signed a memorandum of understanding with Doctor Anywhere, and was awarded e-pharmacy license for WellAway Pharmacy. Other than telemedicine and perhaps onboarding more products / end customers in the B2B platform, are there any other major potential avenues for business growth in the Medical Hypermart segment?

Company's Response

We are still in the early stage of developing the digital business within the Medical Hypermart & Digital business segment. Hence, we will continue to focus on the areas mentioned above to build a leading edge in Singapore before exploring new areas of growth.

Question 6

Is it part of Hyphens' strategy to venture into the area of MedTech/HealthTec, for e.g. collaborating with government organizations (e.g. SG innovate) to develop or partner with startups?

Company's Response

We do not have plans in this area at the moment.

Question 7

Regarding the integrated facility in Singapore :

- (a) does it involve manufacturing the products or mainly packaging end products for retail sale?
- (b) does it cater only to Ocean Health products or other proprietary products as well? Will the integrated facility eventually be expanded to cater to the other range e.g. Ceradan / TDF / CG 210?
- (c) is the facility's current capacity enough to cater to the company's expansion plans for the next 5 years?

Company's Response

It is a repackaging facility for most of Ocean Health supplements and TDF products. Ceradan and CG210 are contract manufactured up to the commercial pack size level. The facility has capacity to meet future needs.

Question 8

Were there any supply chain/logistics challenges as a result of the Covid pandemic or the recent Suez Canal incident, both in terms of receiving supplies from Contract Manufacturing Organizations (CMOs) as well as shipping the finished goods to other countries for sale? If so, were there steps undertaken to improve the resilience of the supply chain?

Company's Response

Most of our shipments are by air. Although a couple of shipments were delayed by the Suez incident, there was no material adverse effect.

Question 9

As Hyphens deepens its digital transformation, can the management consider sharing its digital initiatives (and outcomes) especially for the proprietary brands in future annual reports, e.g. outline the increase in the number of social media followers / engagements, number of social media mentions?

Company's Response

Our marketing team tracks these digital parameters, however these are competitively sensitive indicators that we will prefer to keep confidential.

Question 10

As there will not be any more quarterly reporting, would the management consider providing shareholders with at least some form of quarterly business updates?

Company's Response

Yes, we will continue to keep shareholders updated on a timely basis.

Question 11

It is heartening to know that Hyphens put in a lot of effort to engage the investing community. Would the management consider having "live" video sessions (perhaps facilitated through local brokers) with minority shareholders for company updates/results briefings and perhaps Q&A?

Company's Response

We have held webinars with Philip Securities in 2020 to reach out to retail investors. We will continue to look out for similar events to engage with investors.

Question 12

The fixed pay component of the compensation of directors / key management personnel ranges from 75% to 100%. Would the board of directors consider allocating a higher portion of the compensation to the variable component to better align with shareholder value creation?

Company's Response

The Group has put in place a management remuneration structure that aligns with the long-term interest and risk management policies of the Group. Variable performance incentives are tied to the performance of the Group or business unit and the individual's performance. The disclosure in the Corporate Governance Report is the actual remuneration paid and the variable proportion varies.

Question 13

Hyphens markets & sells a range of specialty pharmaceutical products in selected ASEAN countries, and has strong regulatory capabilities as well as significant experience in certain therapeutic areas/ medical specialties. As such,

- (a) Is Hyphens actively seeking to leverage this strong capability to expand the distribution of the specialty pharmaceutical products to the rest of the ASEAN countries (i.e. those in which Hyphens has no direct presence currently)? Other than entrenching Hyphen's position in ASEAN, it may also help to achieve economies of scale.
- (b) Are there plans to synchronise the distribution of its full range of specialty pharmaceutical products across the ASEAN countries (which it has a direct presence)? Taking an example from the IPO prospectus, Vivomixx is marketed and sold in Singapore, whereas Fenosup Lidose are marketed and sold in Singapore, Vietnam, Malaysia, Indonesia and the Philippines. Are there any reasons why Hyphens is not distributing Vivomixx in Vietnam, Malaysia, Indonesia and the Philippines? Is it because the brand principals already appointed distributors in those countries or is it due to insufficient market demand or some other reasons?

Company's Response

The Group is open to exploring other countries in ASEAN where we currently do not have a presence. We will weigh the opportunities vs costs before making inroads. Similarly we are also open to extending our collaborations with the specialty pharma principals to other countries, subject to factors such as market demand, local regulatory regulations, etc. We have extended such collaborations in the past, e.g. we first distributed contrast media products from Guerbet in Vietnam and this partnership is now extended to Indonesia.

Question 14

Last year, Hyphens expanded the Ocean Health distribution to Sri Lanka / HK / Macau / Duty free in China. Are the results (sales / brand awareness) encouraging so far? Are there any lessons learnt in terms of penetrating a new market, which the Group can incorporate into future expansion plans?

Company's Response

As we have indicated in our press release, we do not expect a material effect on the financials of the Group in the immediate year as it typically takes time to market and gain traction in a new market.

Question 15

In the IPO prospectus, it was mentioned that Ocean Health products are sold in online marketplaces such as ICBC mall, JD worldwide, Lazada:

- (a) Is Hyphens considering/ exploring other online platforms like Tmall/Taobao especially for the China market? If so, are there plans to participate in the Alibaba's 11.11 event?
- (b) How well received is Ocean Health brand/products in the China market so far?
- (c) What types of marketing efforts (online/offline) has been employed for the China market so far?

Company's Response

Efforts for Ocean Health to make inroads into the China market have been challenging. We are constantly exploring opportunities in the Chinese market and are continuously looking out for and assessing the right partner and business model, which takes time.

Question 16

Is the full range of Ocean Health products Halal-Certified?

Company's Response

Not the full range but our flagship product, Omega-3 Fish Oil, is Halal-Certified.

Question 17

While browsing Ceradan products in Guardian retail stores, I noticed different products have various country labelling, e.g. some packages are labelled "Developed in Japan; Made in Singapore" whereas some are labelled "Marketed by Singapore, Malaysia/ Vietnam; Imported by and distributed by Indonesia / Philippines". Can the management please clarify:

- (a) where are Ceradan products manufactured and packaged in? Are Ceradan products in our local Singapore Guardian retail stores imported from Indonesia/Philippines but made in Singapore?
- (b) what is the difference between the country offices that market vs those which import / distribute?
- (c) Is the R&D for all the Ceradan products done (outsourced) in Japan which developed the formulation (except for the hand cream formulation, which is a collaboration with A*STAR) ?

Company's Response

Ceradan products are developed in Japan and manufactured & packed in Singapore. Reason for stating the various ASEAN countries on the packaging is because we are sharing a common packaging across the countries and it is a regulatory requirement to state the licence holder in each country.

Question 18

CG210 is available in retail channels only in Malaysia. Are there plans to bring the CG 210 range into the retail channels in Singapore (similar to Ceradan/Ocean Health brands)?

Company's Response

Yes, we are open to consider at an appropriate time, especially when new SKUs become available.

Question 19

The TDF brand seems to have a long history and was acquired by Hyphens in 2016. Is Hyphens targeting to expand TDF range sold unto the retail channel in the foreseeable future? If so, can management please share some of the initiatives planned? If not, what are the reasons, for e.g. not suitable due to the nature (e.g. controlled ingredients) of the product?

Company's Response

Dermocosmetic is a very fragmented and crowded market, especially in the consumer channel. Hence, TDF is positioned as a medically recommended brand that we market mainly to medical professionals and make available only in selective pharmacies. We will review this positioning and strategy from time to time.

Question 20

Hyphens has launched the Ceradan / TDF websites - are there plans to enable ecommerce (online purchase) function on those sites like for Ocean Health? If not, are there any particular reasons?

Company's Response

Ceradan is readily available on e-commerce platforms like Shopee, Lazada, Qoo10, etc.

Question 21

Are there plans to launch a CG 210 website (with/without ecommerce function)?

Company's Response

No plans at the moment.

Question 22

Are there plans to launch mobile apps for the proprietary products (e.g. Ceradan, Ocean Health), given the high penetration of mobile devices usage?

Company's Response

iControl Eczema app is developed by Hyphens to help patients assess their eczema severity on a daily basis and facilitate interactive eczema management between medical professionals and patients.

Question 23

Ceradan has its own website as well as Facebook/Youtube/Instagram channels and is marketed primarily through medical professionals:

- (a) are there plans to expand its digital ecosystem, perhaps showcasing online videos of customer testimonies or work with influencers ?
- (b) are there plans to establish country specific website / facebook page based on the native language of the country(e.g. Malay, Vietnamese) ?
- (c) are there also plans to feature educational content (videos/text) by dermatologists in all the native countries where Ceradan are sold ?

Company's Response

We have regular engagements with doctors, influencers and Ceradan users to share their experience with others. Respective countries use local languages to reach their doctors and consumers more effectively.

Question 24

Although the China market holds enormous opportunities, it is also very competitive. As such, can the management please share the China expansion /marketing strategy for Ceradan:

- (a) Offline: Is Hyphens only marketing Ceradan through medical channels in China (via Shanghai Good Luck)? What are some of the offline marketing initiatives planned, for e.g. distribute free samples to new mothers in maternity hospitals or roadshows/seminars to help promote brand/product awareness, hosting roadshows?
- (b) Online: Can the management share more about its online (digital) initiatives for Ceradan, for e.g. any plans to leverage on popular platforms like WeChat, Xiaohongshu for brand awareness/engagement or working with Key Opinion Leaders (KOL)?
- (c) How does the company position/differentiate Ceradan products vs other local China products (perhaps including Traditional Chinese Medicine) and other premium Europe / USA imported eczema products in China?
- (d) Although the expansion to China started late last year, how is the reception to the Ceradan products so far (perhaps to the medical professionals)? Does the “Top-Of-Mind” branding in Singapore resonate with the China medical professionals / audience?

Company’s Response

Hyphens supports our appointed distributor, Shanghai Good Luck, in both online and offline engagements with customers in China. Ceradan is now featured on WeChat and Xiaohongshu.

Question 25

Where/How is Ceradan sold in China:

- (a) Offline: Other than medical channels (hospitals/clinics), are the products available for sale via retail pharmacies (in shopping centers) like in Singapore?
- (b) Online: Are there plans for Ceradan products sold in popular online platforms like Tmall/Taobao this year and plans for Ceradan to participate in this year’s Alibaba’s 11.11 event in China this year?

Company’s Response

Ceradan is currently available on Tmall.

Question 26

Is there any specific reason to only market TDF Fairence to the Korea market, e.g. is it because there is currently not many hyperpigmentation brands in Korea? Is there potential to expand the rest of the TDF range in Korea?

Company’s Response

TDF Fairence is a novel Tranexamic Acid cream enhanced with patented XCELAREV® delivery system for melisma. It is proven to deliver 11x higher penetration of key ingredients to the deeper skin layers¹. Hence, it is the first product that we are introducing to the South Korea market with potential to expand to the full range of TDF products.

¹ Ng SP, et al. In vitro human skin concentrations following topical application of 2% tranexamic acid in co-enhancer cream and branded cream formulations. J Cosmet Dermatol. 2020;00:1–7.

Question 27

Is there a specific overseas expansion playbook Hyphens follow before embarking unto a new market (country):

- (a) How does Hyphens gauge the potential demand of its proprietary products in a new market? Does Hyphens engage a 3rd party external consultant for such purposes?
- (b) How does Hyphens consider and decide on the appropriate marketing strategies (presumably localized to the country)? Is it done in consultation with the appointed distributors?
- (c) Are the brand awareness/ marketing campaigns done solely by the distributors (e.g. Shanghai Good Luck", JSPharma, SUTL) or spearheaded by Hyphens?
- (d) What are some of the challenges Hyphens face when searching/ appointing distributors for a new market (country)?
- (e) The climate differs in equatorial Asia region (e.g. Singapore) compared to the northern parts of Asia (e.g. China). Consequently, there may be varying customer preferences in terms of texture of the skin care products. Does Hyphens think it is a potential issue to be addressed for the Ceradan / TDF range, and if so how?

Company's Response

Internationalisation is a key growth strategy of the Group. The business development team spearheads market entry into new countries through working with Enterprise Singapore, market consultants and tapping on the Group's network of KOLs, distributors and principals.

After distributors have been identified and appointed in each country, our Hyphens team in Singapore works hand in hand with the distributors to drive marketing campaigns in the local countries.

Question 28

How does Hyphens track and evaluate the effectiveness of the appointed distributors (e.g. Shanghai Good Luck/ JSPharma / SUTL), for e.g. what are some of the key performance indicators to measure the success of brand awareness or sales?

Company's Response

There are various performance measurements that we use to monitor the distributors and sales offtake is one of them.